A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model

Chemical Biology and Drug Design

Volumn 76, Issue 3, 2010, Pages 234-244

  Satyanarayanajois, Seetharama D ^a   Büyüktimkin, Barlas ^b   Gokhale, Ameya ^a   Ronald, Sharon ^a   Siahaan, Teruna J ^b   Latendresse, John R ^c  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

arthritis mouse model; beta hairpin; CD2 peptides CD2; CD58; cell adhesion; immunomodulation; NMR

Indexed keywords

CD2 ANTIGEN; CELL ADHESION MOLECULE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PEPTIDE DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA SHEET; CELL ADHESION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RHEUMATOID ARTHRITIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD2; ANTIGENS, CD58; ARTHRITIS, EXPERIMENTAL; BINDING SITES; CACO-2 CELLS; CELL ADHESION; FEMALE; HUMANS; MICE; MICE, INBRED DBA; MODELS, ANIMAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, SECONDARY;

MUS;

EID: 77955257453     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01001.x     Document Type: Article

References (41)

1. Springer T.A. (1990) Adhesion receptors of the immune system. Nature 346 : 425 434.
2. Bierer B.E., Burakoff S.J. (1998) T cell adhesion molecules. FASEB J 2 : 2584 2590.
3. Anderson M.E., Siahaan T.J. (2003) Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24 : 487 501.
4. Kamradt T., Mitchison N.A. (2001) Tolerance and autoimmunity. N Engl J Med 344 : 655 661.
5. Mcmurray R.W. (1996) Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 25 : 215 233.
6. Cemerski S., Shaw A. (2006) Immune synapse in T-cell activation. Curr Opin Immunol 18 : 1 7.
7. Van der Merwe P.A., Davis S.J. (2003) Molecular interactions mediating T cell antigen. Annu Rev Immunol 21 : 659 684.
8. Kannan K., Ortmann R.A., Kimpel D. (2005) Animal model of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12 : 167 181.
9. Takahashi H., Soderstrom K., Nilsson E., Kiessling R., Patarroyo M. (1992) Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients. Eur J Immunol 22 : 2879 2885.
10. Hale L.P., Martin M.E., McCollum D.E., Nunley J.A., Springer T.A., Singer K.H., Haynes B.F. (1989) Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum 32 : 22 30.
11. Hoffmann J.C., Bayer B., Zeidler H. (1996) Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 104 : 460 466.
12. Mojcik C.F., Shevach E. (1997) Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 6 : 991 1004.
13. Przepiorka D., Phillips G.L., Ratanatharathorn V., Cottler-Fox M., Sehn L.H., Antin J.H., LeBherz D., Awwad M., Hope J., McClain J.B. (1998) A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 92 : 4066 4071.
14. Hoffmann J.C., Herklotz C., Zeidler H., Bayer B., Rosenthal H., Westermann J. (1997) Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34. Ann Rheum Dis 56 : 716 722.
15. Sido B., Dengler T.J., Otto G. (1998) Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production. Eur J Immunol 28 : 1347 1357.
16. Squifflet J.P., Besse T., Malaise J., Mourad M., Delcorde C., Hope J.A., Pirson Y. (1997) BTI-322 for induction therapy after renal transplantation: a randomized study. Transplant Proc 29 : 317 319.
17. Mourad M., Besse T., Malaise J., Baldi A., Latinne D., Bazin H., Pirson Y., Hope J., Squifflet J.P. (1997) BTI-322 for acute rejection after renal transplantation. Transplant Proc 29 : 2353.
18. Mrowietz U. (2002) Treatment targeted to cell surface epitopes. Clin Exp Dermatol 27 : 591 596. (Pubitemid 35463876)
19. Braun J., Sieper J. (2003) Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. Biodrugs 17 : 187 199.
20. Leader B., Baca Q.J., Golan D.E. (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7 : 21 39.
21. Hruby V.J. (2002) Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov 1 : 847 856.
22. Liu J., Li C., Ke S., Satyanarayanajois S.D. (2007) Structure-based rational design of beta-hairpin peptides from discontinuous epitopes of cluster of differentiation 2 (CD2) protein to modulate cell adhesion interaction. J Med Chem 50 : 4038 4047.
23. Giddu S., Subramanian V., Yoon H.S., Satyanarayanajois S.D. (2009) Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem 52 : 726 736.
24. Li C., Satyanarayanajois S.D. (2007) Structure-function studies of peptides for cell adhesion inhibition: identification of key residues by alanine mutation and peptide-truncation approach. Peptides 28 : 1498 1508.
25. Wang J., Smolyar A., Tan K., Liu J., Kim M., Sun Z.J., Wagner G., Reinherz E.L. (1999) Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell 97 : 791 803.
26. Davis S.J., Davies E.A., Tucknott M.G., Jones E.Y., van der Merwe P.A. (1998) The role of charged residues mediating low affinity protein-protein recognition at the cell surface by CD2. Proc Natl Acad Sci USA 95 : 5490 5494.
27. Kim M., Sun Z.Y., Byron O., Campbell G., Wagner G., Wang J., Reinherz E.L. (2001) Molecular dissection of the CD2-C58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional "hot spot". J Mol Biol 312 : 711 720.
28. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 5 : 55 63.
29. Riss T., Moravec R., Niles A. (2005) Selecting cell-based assays for drug discovery screening. Cell Notes 13 : 16 21.
30. Moore J.M. (1999) NMR Techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery. Biopolymers 51 : 221 243.
31. Post C.B. (2003) Exchange-transferred NOE spectroscopy and bound ligand structure determination. Curr Opin Struct Biol 13 : 581 588.
32. Wuthrich K. NMR of Proteins and Nucleic Acids. New York : John Wiley & Sons, 1986.
33. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19 : 1639 1662.
34. Brand D.D., Latham K.A., Rosloniec E.F. (2007) Collagen-induced arthritis. Nat Protoc 2 : 1269 1275.
35. Srinivasan M., Eri R., Zunt S.L., Summerlin D.-J., Brand D.D., Blum J.S. (2007) Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent. Arthritis Rheum 56 : 498 508.
36. Morris C.J. (2003) Carrageenan-induced paw edema in the rat and mouse. In : Winyard P.G., Willoughby D.A., editors. Inflammation Protocols, Methods in Molecular Biology. Totowa, NJ : Humana Press Inc., Vol. 225 pp. 115 121.
37. Alba E.D., Rico M., Jimenez M.A. (1999) The turn sequences directs beta-strand alignment in designed beta-hairpins. Protein Sci 8 : 2234 2244.
38. Rai R., Aravinda S., Kanagarajadurai K., Raghothama S., Shamala N., Balaram P. (2006) Diproline templates as folding nuclei in designed peptides. Conformational analysis of synthetic peptide helices containing amino terminal Pro-Pro segments. J Am Chem Soc 128 : 7916 7928.
39. Mayo K.H., Dings R.P.M., Flader C., Nesmelova I., Hargittai B., van der Schaft D.W.J., van Eijk L.I., Walek D., Haseman J., Hoye T.R., Griffioen A.W. (2003) Design of a Partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 278 : 45746 45752.
40. DeLano W.L. (2002) The PyMOL Molecular Graphics System. San Carlos, CA, USA : DeLano Scientific, http://www.pymol.org.Pymol.
41. Kobayashi N., Kobayashi H., Gu L., Malefyt T., Siahaan T.J. (2007) Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J Pharmacol Exp Ther 322 : 879 886.